1. Revisiting the Role of Immunotherapy for Colorectal Cancer Treatment in Patients with Constitutional Mismatch Repair Deficiency
- Author
-
Eikenboom, Ellis L, Michiels, Erna M C, Grünhagen, Dirk J, de Vries, Marianne, Wagner, Anja, Spaander, Manon CW, Clinical Genetics, Gastroenterology & Hepatology, Surgery, and Radiology & Nuclear Medicine
- Subjects
SDG 3 - Good Health and Well-being ,General Earth and Planetary Sciences ,General Environmental Science - Abstract
Patients with constitutional mismatch repair deficiency syndrome(CMMRD) usually develop multiple tumors at a young age. Chemotherapywas previously shown to be less effective in these tumors. Recent reportssuggest immunotherapeutic treatment in CMMRD-associated tumors. Here,we present a CMMRD patient, successfully treated with immunotherapyfor metastasized colorectal cancer (CRC). A young adolescent male wasdiagnosed with T2N2M1 cecum carcinoma with liver metastases. Hereceived four initial doses of nivolumab (3 mg/kg) with ipilimumab (1 ml/kg) every three weeks, followed by 41 doses of nivolumab alone every twoweeks. A complete response was achieved; also pathological assessmentof removed liver metastases was indicative of a complete response. Atthe time of writing, 14 months after end of treatment, the CRC had notrecurred. Immunotherapeutic treatment resulted in a complete response ofthe primary CRC and metastases. Immunotherapy as first line treatmentshould be strongly considered in treatment of CMMRD-associated CRCs
- Published
- 2022
- Full Text
- View/download PDF